C4 Therapeutics, Inc. Proceeds from Stock Options Exercised
C4 Therapeutics, Inc. (CCCC) reported Proceeds from Stock Options Exercised of $781.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-11
- C4 Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-06-30 was $176.00K.
- C4 Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-03-31 was $605.00K.
- C4 Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- C4 Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-09-30 was $107.00K, a 723.08% increase year-over-year.
- C4 Therapeutics, Inc. proceeds from stock options exercised for fiscal 2025 was $107.00K, a 86.25% decline from fiscal 2024.
- C4 Therapeutics, Inc. proceeds from stock options exercised for fiscal 2024 was $778.00K, a 1241.38% increase from fiscal 2023.
- C4 Therapeutics, Inc. proceeds from stock options exercised for fiscal 2023 was $58.00K, a 92.54% decline from fiscal 2022.
- C4 Therapeutics, Inc. proceeds from stock options exercised for fiscal 2022 was $777.00K, a 66.65% decline from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $781.00K 10-Q · filed 2026-08-11 | $781.00K derived: sum of 3 quarters · filed 2026-08-11 | $888.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $605.00K 10-Q · filed 2026-05-12 | $605.00K derived: sum of 2 quarters · filed 2026-05-12 | $712.00K derived: sum of 3 quarters · filed 2026-05-12 | $712.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $107.00K derived: sum of 2 quarters · filed 2026-02-26 | $107.00K derived: sum of 3 quarters · filed 2026-08-11 | $107.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $107.00K derived: sum of 2 quarters · filed 2026-08-11 | $107.00K 10-Q · filed 2025-11-06 | $218.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $111.00K derived: sum of 3 quarters · filed 2026-08-11 | $124.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $111.00K derived: sum of 2 quarters · filed 2026-05-12 | $124.00K derived: sum of 3 quarters · filed 2026-05-12 | $259.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $124.00K derived: sum of 2 quarters · filed 2026-02-26 | $259.00K derived: sum of 3 quarters · filed 2026-02-26 | $778.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $148.00K derived: sum of 2 quarters · filed 2025-11-06 | $667.00K 10-Q · filed 2025-11-06 | $667.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $654.00K 10-Q · filed 2025-08-07 | $654.00K derived: sum of 3 quarters · filed 2025-08-07 | $654.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $519.00K 10-Q · filed 2025-05-07 | $519.00K derived: sum of 2 quarters · filed 2025-05-07 | $519.00K derived: sum of 3 quarters · filed 2025-05-07 | $521.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $2.00K derived: sum of 3 quarters · filed 2025-02-27 | $58.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.00K derived: sum of 2 quarters · filed 2024-10-31 | $58.00K 10-Q · filed 2024-10-31 | $105.00K derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $58.00K 10-Q · filed 2024-08-01 | $105.00K derived: sum of 3 quarters · filed 2024-08-01 | $316.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $56.00K 10-Q · filed 2024-05-08 | $103.00K derived: sum of 2 quarters · filed 2024-05-08 | $314.00K derived: sum of 3 quarters · filed 2024-05-08 | $573.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $258.00K derived: sum of 2 quarters · filed 2024-02-22 | $517.00K derived: sum of 3 quarters · filed 2024-02-22 | $777.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $211.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $470.00K derived: sum of 2 quarters · filed 2023-11-01 | $730.00K 10-Q · filed 2023-11-01 | $1.48M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $519.00K 10-Q · filed 2023-08-08 | $1.27M derived: sum of 3 quarters · filed 2023-08-08 | $2.14M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $260.00K 10-Q · filed 2023-05-04 | $1.01M derived: sum of 2 quarters · filed 2023-05-04 | $1.89M derived: sum of 3 quarters · filed 2023-05-04 | $2.42M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $752.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.63M derived: sum of 2 quarters · filed 2023-02-23 | $2.16M derived: sum of 3 quarters · filed 2023-02-23 | $2.33M 10-K · filed 2023-02-23 |
| 2021-09-30 | $873.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.41M derived: sum of 2 quarters · filed 2022-11-03 | $1.58M 10-Q · filed 2022-11-03 | $1.70M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $539.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $705.00K 10-Q · filed 2022-08-04 | $828.00K derived: sum of 3 quarters · filed 2022-08-04 | $1.36M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $166.00K 10-Q · filed 2022-05-05 | $289.00K derived: sum of 2 quarters · filed 2022-05-05 | $821.00K derived: sum of 3 quarters · filed 2022-05-05 | $897.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $655.00K derived: sum of 2 quarters · filed 2022-02-24 | $731.00K derived: sum of 3 quarters · filed 2022-02-24 | $887.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $532.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $608.00K derived: sum of 2 quarters · filed 2021-11-10 | $764.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $232.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $156.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $274.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |